15 completed, 7 unknown, 5 terminated, 2 withdrawn. 30 Phase 3, 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 30 | Completed 15, Unknown 7, Terminated 5, Withdrawn 2, Active not recruiting 1 |
| Phase 2 | 10 | Completed 4, Unknown 3, Withdrawn 2, Terminated 1 |
Follow Hypertrophy: new trials by email Literature Review of Hypertrophy trials Research Report on Hypertrophy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intra-lesional ACE Inhibitor for Treatment of Hypertrophic Scars Intralesional enalaprilat injection - Hypertrophic Scar | Phase 2 / Phase 3 | Withdrawn | Nova Scotia Health Authority | 2024-08-01 | 2025-02-17 | |
| Efficacy of Angiotensin Receptor Blocker Following aortIc Valve Intervention for Aortic STenOsis: a Randomized mulTi-cEntric Double-blind Phase II Study Valsartan, Placebo Oral Tablet - Aortic Valve Stenosis, Valsartan | Phase 2 / Phase 3 | Withdrawn | University Hospital, Limoges | 2023-01-02 | 2023-03-17 | |
| Effect of Dapagliflozin on Myocardial and Renal Function Following Aortic Valve Stenosis Intervention SGLT2 inhibitor, Placebo - Aortic Stenosis, Left Ventricle Hypertrophied | Phase 2 / Phase 3 | Unknown | University of Aarhus | 106 | 2022-02-12 | 2022-02-15 |
| A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Pacritinib, Physician's Choice medications - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 3 | Active not recruiting | Swedish Orphan Biovitrum | 407 | 2017-06-26 | 2026-04-30 |
| Systemic Hormones and Muscle Protein Synthesis Sustanon 250, Zoladex, Placebo - Sarcopenia, Muscle Hypotrophy | Phase 3 | Unknown | University of Nottingham | 34 | 2016-12-15 | 2019-02-26 |
| Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy Eleclazine, Placebo - Hypertrophic Cardiomyopathy | Phase 2 / Phase 3 | Terminated | Gilead Sciences | 172 | 2015-02-05 | 2018-09-24 |
| Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia Pacritinib, Best Available Therapy - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 3 | Terminated | CTI BioPharma | 311 | 2014-02-01 | 2021-11-18 |
| Silicone Gel Versus Onion Extract Gel as Prevention for Postsurgical Scars Silicone gel Kelo-cort™;, Onion extract gel Contractubex™ - Hypertrophic or Keloid Scars | Phase 3 | Completed | CHA University | 90 | 2013-04-01 | 2019-08-28 |
| Pacritinib Versus Best Available Therapy to Treat Myelofibrosis Pacritinib, Best Available Therapy - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 3 | Terminated | CTI BioPharma | 327 | 2013-01-01 | 2020-09-29 |
| Running Effect on Cardiovascular and Muscular Parameters exercise - Males, Untrained | Phase 3 | Completed | University of Erlangen-Nürnberg Medical School | 80 | 2011-07-01 | 2012-08-14 |
| Myocardial Protection With Perhexiline in Left Ventricular Hypertrophy Perhexiline, Placebo marked PEXSIG - Myocardial Reperfusion Injury, Cardiac Output, Low | Phase 2 / Phase 3 | Unknown | University Hospital Birmingham | 220 | 2009-10-01 | 2011-08-11 |
| Angiotensin-converting-enzyme (ACE) Inhibitors in Hemodialysis ACE inhibitor Ramipril, non-RAS inhibitor antihypertensive therapy - Left Ventricular Hypertrophy, Hypertension | Phase 3 | Completed | Mario Negri Institute for Pharmacological Research | 269 | 2009-05-01 | 2021-01-11 |
| The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5 paricalcitol injection 4 mcg/mL, Placebo Injection 4 mcg/mL - Chronic Kidney Disease (CKD) Stage 5, Hypertrophy, Left Ventricular | Phase 3 | Terminated | Abbott | 12 | 2009-01-01 | 2012-01-20 |
| Effects of High Dose Atorvastatin in Patients With Surgical Aortic Stenosis Atorvastatin 80 mg - Aortic Valve Stenosis, Ventricular Hypertrophy | Phase 3 | Unknown | University Hospital, Strasbourg, France | 60 | 2008-12-01 | 2015-06-19 |
| Open-Label Extension of LOCKCYST Trial lanreotide - Polycystic Liver Disease, Hepatomegaly | Phase 2 / Phase 3 | Unknown | Radboud University Medical Center | 54 | 2008-04-01 | 2008-11-13 |
| Importance of Aldosterone in the Pathogenesis of Hypertensive Heart Disease spironolactone, placebo - Primary Hypertension | Phase 3 | Completed | University of Erlangen-Nürnberg Medical School | 50 | 2008-03-01 | 2012-07-10 |
| The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4 paricalcitol, placebo - Chronic Kidney Disease, Left Ventricular Hypertrophy | Phase 3 | Completed | AbbVie (prior sponsor, Abbott) | 227 | 2008-02-01 | 2013-03-12 |
| Lanreotide as Treatment of Polycystic Livers Placebo, Lanreotide - Polycystic Liver Disease, Hepatomegaly | Phase 2 / Phase 3 | Completed | Radboud University Medical Center | 38 | 2007-10-01 | 2009-02-17 |
| Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy Valsartan, Amlodipine, Hydrochlorothiazide - Hypertension; Hypertrophy, Left Ventricular | Phase 3 | Completed | Novartis | 90 | 2007-03-01 | 2011-05-11 |
| Octreotide in Severe Polycystic Liver Disease Octreotide, Placebo - Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease | Phase 2 / Phase 3 | Completed | Mayo Clinic | 42 | 2007-01-01 | 2012-11-21 |
Showing 20 of 30. Sign in to see all of them.
Hypertrophy, Left Ventricular (18) · Hypertension (7) · Aortic Valve Stenosis (5) · Anemia (4) · Bone Marrow Diseases (3) · Hematologic Diseases (3) · Hepatomegaly (3) · Liver Diseases (3) · Polycystic liver disease (3) · Primary Myelofibrosis (3) · Splenomegaly (3) · Cardiomegaly (2) · Cardiomyopathy, Hypertrophic (2) · Hemorrhagic Disorders (2)
Pathological Conditions, Anatomical (30) · Pathological Conditions, Signs and Symptoms (30) · Heart Diseases (21) · Cardiovascular Diseases (20) · Cardiomegaly (18) · Vascular Diseases (11) · Female Urogenital Diseases (8) · Female Urogenital Diseases and Pregnancy Complications (8) · Kidney Diseases (8) · Male Urogenital Diseases (8) · Urogenital Diseases (8) · Urologic Diseases (8) · Aortic Valve Disease (7) · Heart Valve Diseases (7)
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (3) · Atenolol (3) · Lisinopril (2) · Losartan (2) · Valsartan (2) · lanreotide (2) · paricalcitol (2) · Adrenal Cortex Hormones (1) · Amlodipine (1) · Atorvastatin (1) · Danazol (1) · Diltiazem (1) · Duration of Therapy (1) · Enalaprilat (1) · Epoetin Alfa (1)
CTI BioPharma (2) · Radboud University Medical Center (2) · University of Erlangen-Nürnberg Medical School (2) · AbbVie (prior sponsor, Abbott) (1) · Abbott (1) · Azienda Ospedaliera, Universitaria Policlinico Vittorio Emanuele (1) · Brigham and Women's Hospital (1) · CHA University (1) · Gilead Sciences (1) · GlaxoSmithKline (1) · Heidelberg University (1) · Indiana University (1) · Janssen-Ortho Inc., Canada (1) · Karolinska Institutet (1) · Mario Negri Institute for Pharmacological Research (1)
United States (11) · Germany (10) · Italy (9) · United Kingdom (8) · France (7) · Australia (6) · Czechia (6) · Russia (6) · Netherlands (5) · Belgium (4) · Hungary (4) · Poland (4) · Spain (4) · Romania (3) · Sweden (3)
Frederik Nevens, MD, PhD (2) · Loes van Keimpema, MSc (2) · Simran Singh (2) · Ann Eldred, MD (1) · Beth Ziemba (1) · Carmelita Marcantoni, M.D. (1) · Carolyn Y Ho, MD (1) · Dennis Andress, MD (1) · Domeinco Pagano, MD FRCS (1) · Franz Schaefer, MD (1) · Henrik Nissen, MD, PhD (1) · Jacob E Moller, Md, Ph.D (1)
PMID 18591942, PMID 33275766, PMID 39356039, PMID 11403367, PMID 12172314, PMID 12423712, PMID 14630977, PMID 14639093, PMID 14700505, PMID 14704728, PMID 14744931, PMID 15253184, PMID 15253732, PMID 15647341, PMID 15716707, PMID 15772249, PMID 16079683, PMID 16093916, PMID 16253719, PMID 16942935, PMID 17444886, PMID 17637792, PMID 17762662, PMID 18464745, PMID 19332468, PMID 19486119, PMID 19621835, PMID 20001655, PMID 20589977, PMID 20601389, PMID 21239405, PMID 21242674, PMID 21304095, PMID 21353251, PMID 21358415, PMID 21720264, PMID 21746765, PMID 22243363, PMID 22337679, PMID 22495466, PMID 22695506, PMID 22753219, PMID 22773240, PMID 22869821, PMID 23194491, PMID 23316326, PMID 23403268, PMID 24084214, PMID 24173271, PMID 24379001
2008 (1), K23HL078901 (1), R01DK062030 (1), UL1RR024150 (1)